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Abstract
Background: Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-remission
treatment for adults with high-risk acute lymphoblastic leukemia (ALL). The aim of the study was to analyze results
of unmanipulated haploidentical allo-SCT (haplo-SCT) for adults with ALL and to identify prognostic factors.
Methods: We performed a retrospective analysis on 208 adults transplanted in EBMT centers from 2007 to 2014.
Results: Median age at haplo-SCT was 32 years and median follow-up, 31 months. Forty-four percent of the patients
were in first complete remission (CR1). Stem cell source was the bone marrow (BM) for 43% and peripheral blood (PB)
for 57% of patients. Myeloablative conditioning (MAC) was used for 66% and reduced intensity regimen (RIC) for 34%
of patients. GVHD prophylaxis was based on post-transplant cyclophosphamide (PT-Cy) for 118 (57%) or on anti-
thymocyte-globulin (ATG) for 90 (43%) plus standard prophylaxis. One hundred eighty-four (92%) patients achieved
engraftment. Cumulative incidence (CI) of grade II–IV acute-graft-versus-host-disease (GVHD) was 31%, grade III–IV 11%,
and chronic GVHD 29%. Non-relapse mortality (NRM) and relapse-incidence (RI) were 32 and 37%, respectively. Overall
survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free-survival (GRFS) at 3 years were 33, 31, and 26%.
For patients in CR1, OS, LFS, and GRFS were 52, 47, and 40%, respectively. Disease status was the main factor associated
with transplant outcomes. Use of BM was independently associated with improvement in NRM, acute GVHD, GRFS, LFS,
and OS.
Conclusions: Unmanipulated haplo-SCT may be considered a valid option for adult patients with high-risk ALL lacking
HLA identical donor preferably in early disease status.
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Background
Acute lymphoblastic leukemia (ALL) has a high fre-
quency in children and young adults [1–3] and is rare in
adults. Childhood ALL is associated with cure rates
higher than 80%, while in adult patients’ cure rates range
between 20 and 40% with high incidence of relapse and
dismal prognosis [4, 5]. Some of the differences between
childhood and adult ALL are related to the biology of
the disease, treatment, and patient-related factors. Adverse
genetic features in adults predispose to chemotherapy
resistance and disease relapse after an initial achievement
of complete remission (CR). Other factors are the high inci-
dence of comorbidities and treatment-related side effects
that may result in the administration of lower cumulative
doses of chemotherapy [4].
Approximately 80% of the patients with adult ALL
achieve first CR (CR1); however, the major barrier to long-
term survival is the disease recurrence which is over 60%
with a median overall survival (OS) of <10 months [6].
Besides some controversy on indication and timing,
allogenic hematopoietic stem cell transplantation (allo-
SCT) is the standard of care for high-risk patients in
CR1 and all patients who experience relapse [7–12].
The most suitable donor for transplantation is an HLA-
matched sibling or fully matched (10/10 HLA matched)
unrelated donor (MUD). However, for patients who lack
HLA matched sibling or MUD, allo-SCT from un haploi-
dentical or cord blood donor, is a possible option [13, 14].
Haploidentical hematopoietic stem cell transplantation
(haplo-SCT) is increasingly used [15] since it allows
almost all patients in need for an allo-SCT to undergo
allo-SCT. Haploidentical donors (siblings, children, par-
ents, and extended relatives) are virtually available for all
patients, and the access to further stem cell donations or
donor lymphocyte infusions (DLIs) or other types of
adoptive cellular therapies is easily available.
In the last decade, unmanipulated grafts without T cell
depletion (TCD) have been used more frequently in the
haplo-setting with the use of anti-thymocyte globulins
(ATG) or post-transplant cyclophosphamide (PT-Cy) as
GVHD prophylaxis with encouraging results [16–21].
Furthermore, the optimization of conditioning regimens
with the development of reduced intensity conditioning
(RIC) including for haplo-SCT, have further extended
the use of haplo-SCT to older patients and those with
significant pre-transplant comorbidities [22].
Several single-center- and registry-based studies showed
comparable outcomes between haplo-SCT and mis-
matched (9/10 HLA compatibility) unrelated donor or
cord blood transplants in patients with acute leukemias
[23–25]. However, few studies, so far, analyzed the results
of haplo-SCT in adult ALL.
In a recent report by Srour et al. [26], outcomes of 109
adults with ALL receiving haplo-SCT with PT-Cy as
GVHD prophylaxis were reported with encouraging
results. We conducted a registry-based study of adults
with ALL transplanted in EBMT centers using unmanip-
ulated haplo-SCT with PT-Cy or ATG as GVHD
prophylaxis and MAC or RIC as conditioning regimens.
Methods
Study design
This is a retrospective registry-based analysis on be-
half of the ALWP of EBMT on haplo-SCT, in adult
patients with ALL, performed between January 2007
and December 2014.
The EBMT is a voluntary working group of more than
500 transplant centers that are required to report all
consecutive stem cell transplantations and follow-ups
once a year. Audits are routinely performed to deter-
mine the accuracy of the data.
Patients included into the study, fulfilled all of the
following criteria: age ≥18 years; de novo ALL; first allo-
SCT, host–donor number of HLA mismatches ≥2;
peripheral blood (PB) or bone marrow (BM) grafts and
no ex vivo T cell depletion.
Minimal residual disease (MRD) was defined as any
evidence of detectable disease by cytogenetics, flow-
cytometry, and/or polymerase chain reaction (PCR) for
patients in morphologic remission at transplant.
MAC was defined as a regimen containing either total
body irradiation (TBI) with a dose greater than 6 Gy, a
total dose of oral busulfan (Bu) greater than 8 mg/kg, or
a total dose of intravenous Bu greater than 6.4 mg/kg or
melphalan at doses >140 mg/m2. In addition, regimens
containing two alkylating agents were considered as
MAC. All other regimens were defined as RIC [27].
Statistical analysis
The primary endpoint was leukemia-free survival (LFS).
Secondary endpoints were overall survival (OS), refined
graft-versus-host-free, relapse-free survival (GRFS), neu-
trophil engraftment, acute (a)GVHD and chronic
(c)GVHD, relapse incidence (RI), and non-relapse mor-
tality (NRM).
LFS was defined as the interval from haplo-SCT to
either relapse or death in remission. OS was defined as
the time to death from all causes. GRFS events have
been defined as grade 3–4 acute GVHD, severe chronic
GVHD, disease relapse, or death from any cause after
SCT [28]. Engraftment was defined as the first of three
consecutive days with an absolute neutrophil count
>0.5 × 109/l. aGVHD was graded according to the modi-
fied Glucksberg criteria [29] and cGVHD according to
the revised Seattle criteria [30].
Cumulative incidence (CI) of relapse and NRM was
calculated from the date of transplant to the date of re-
lapse or death in remission, respectively, with the other
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event being the competing risk. For studying GVHD,
both relapse and death were considered as competing
events.
Univariate comparisons of time-dependent endpoints
were done using the log-rank test for OS and LFS and
GRFS and the Gray’s test for cumulative incidence
functions.
A multivariate analysis was performed using Cox pro-
portional hazards model. Variables were included in the
multivariate model if they were conceptually important
or if they approached or attained statistical significance
by univariate analysis. All tests are two-sided. The type I
error rate was fixed at 0.05 for determination of factors
associated with time to event.
In order to test for a center effect, we introduced a
random effect or frailty for each center into the
model [31, 32].
Statistical analyses were performed with the SPSS
22 (SPSS Inc./IBM, Armonk, NY, USA) and R 3.2.3
(R Development Core Team, Vienna, Austria) soft-
ware packages.
Results
Patients, disease, and transplant characteristics
A total of 208 patients transplanted in 69 EBMT centers
were analyzed, and a median of eight haplo-SCT for each
center was reported. No center effect was found using
the frailty model (p = 0.30). Patient, disease, and trans-
plant characteristics are listed in Table 1.
The median follow-up was 31 (range 2–79) months,
and the median year of haplo-SCT was 2012 (range
2007–2014). Median age at haplo-SCT was 32 (range
18–76) years. The majority of patients (69%) had a
Karnofsky performance status (KPS) ≥90%. Fourteen
(7%) patients received a previous autologous SCT.
For patients with available information (n = 151), 100
(66%) patients had B ALL, and 51 (34%) T ALL.
Disease status at transplantation was CR1 in 91 (44%)
patients, second or more complete remission (CR2+) in
58 (28%) and 59 (28%) patients were in active disease.
Cytogenetic analysis was available for 142 patients: 46
(32%) were Philadelphia positive and 96 (68%) were
Philadelphia negative. Among Philadelphia negative pa-
tients, complete karyotype was reported for 69 patients.
Thirty seven (54%) had a normal karyotype and 32 (46%)
abnormal one. The most common alterations found
were t(1;19) (n = 5), t(4;11) (n = 4), and t(12;21) (n = 2).
For patients with t(9;22), the use of tyrosine kinase in-
hibitors (TKI) was reported in 32 patients before trans-
plant and in 11 patients after transplant, respectively.
Status of MRD at transplant for patients in CR was
available for 91 of 149 patients, and 45 (49%) were MRD
positive.
Conditioning regimen was MAC in 137 patients (66%)
and RIC in 71 patients (34%), respectively. Among
chemotherapy-based regimen TBF (thiotepa 10 mg/kg,
fludarabine 150 mg/m2, busulfan 9.6 mg/kg i.v. for
MAC; Thiotepa 5 mg/kg and busulfan 6.4 mg/kg i.v. for
RIC) were the most commonly used regimens (Table 1).
GVHD prophylaxis was based on either PT-Cy in 118
(57%) or on ATG in 90 (43%) of the patients, respect-
ively, in association with calcineurin inhibitors and my-
cophenolate mofetil (patient characteristics according to
GVHD prophylaxis were shown in Additional file 1:
Table S1). Among patients receiving an ATG-based
GVHD prophylaxis details on the type of ATG was avail-
able for 66 patients (27 received Thymoglobulin and 44
Fresenius). According to the type of ATG, the median
dose of ATG was 10 mg/Kg (total dose) for the thymo-
globulin and 30 mg/Kg (total dose) for the Fresenius.
Stem cell source was peripheral blood (PB) or bone
marrow (BM) in 119 (57%) and 89 (43%) patients,
respectively, (Table 1).
Engraftment and graft-versus-host-disease
Neutrophil engraftment was achieved in 92% of the pa-
tients. Median time to engraftment was 17 (range, 5–47)
days. Seventeen patients (8.5%) experienced graft failure.
The 100-day cumulative incidence (CI) of grade II–IV
aGvHD was 30.6% (95% CI 24.3–37) (Fig. 1a) and 11%
(95% CI 7.1–15.8) for grades III–IV, respectively.
In univariate analysis, the 100-day CI of grade II–IV
aGvHD was different according to the stem cell source,
being 17.3% (95% CI 10.2–26) for BM vs 40.8% (95% CI
31.6–49.7) for PB, grafts (p < 0.01).
Similarly, in the multivariate analysis (Table 2), the use
of PB was significantly associated with an increased risk
of aGVHD (HR 3.00, 95% CI 1.35–6.07, p < 0.01) com-
pared to BM (Additional file 2: Figure S1). RIC condi-
tioning was associated with a reduced risk of aGVHD as
well (HR 0.46, 95% CI 0.23–0.93, p = 0.03).
The 3-year CI of chronic GVHD was 29% (Fig. 1b),
and CI of extensive cGVHD was 10%. No factors were
significantly associated with cGVHD in the multivariate
analysis (Table 2).
Relapse incidence and non-relapse mortality
The 3-year CI of relapse was 37% (Fig. 1c), being
24% in patients in CR1, 32% for those in CR2+, and
60% in patients with advanced disease at transplant-
ation (p < 0.01).
The impact of disease status remained significant in
multivariate analysis (advanced HR 8.04, 95% CI 3.76–
17.19, p < 0.01) and also the combination of female
donor/male recipient was associated with a decreased
risk of relapse in the multivariate analysis (HR 0.39, 95%
CI 0.18–0.84, p = 0.01) (Table 2).
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CI of NRM at 3 years was 32% (Fig. 1d). NRM was not in-
fluenced by disease status at haplo-SCT; it was 29% in CR1,
36% in CR2+, and 34% in patients with advanced disease, re-
spectively, (p= 0.59). One hundred thirty-five patients died,
42 (31%) due to disease recurrence and 93 (69%) from NRM
Forty-eight (52%) patients died from infection, 24
(26%) from GVHD, 4 (5%) from hemorrhage, 1 (1%)
from cardiac toxicity, 2 (2%) from sinusoidal obstruction
syndrome (SOS), 3 (3%) from interstitial pneumonia, 6
(6%) from other transplant-related causes and 5 (5%)
missing (Additional file 3: Table S2). In the multivariate
analysis (Table 2), the risk of NRM was significantly
lower in patients with a Karnofsky performance status
≥90% (HR 0.23, 95% CI 0.11–0.52, p < 0.01). The use
of PB was associated with an increased risk of NRM
(HR 2.56, 95% CI 1.14–5.74, p = 0.02).
OS, LFS, and GRFS
With a median follow-up of 31 months, the probability
of 3-year OS, LFS, and GRFS was 33, 31, and 26%,
respectively.
Table 1 Patients, disease, and transplant characteristics
Variables
Follow-up (months) Median (range) 31 (2–79)
Patient age (years) Median (range) 32 (18–76)
Year of Tx Median (range) 2012 (2007–2014)
Patient sex Female 80 (39%)
Male 127 (61%)
Karnofsky at Tx ≥90% 128 (69%)
Previous autologous Tx Yes 14 (7%)
Disease status at Tx CR1 91 (44%)
CR2+ 58 (28%)
Advanced disease 59 (28%)
Immunophenotype B ALL 100 (66%)
T ALL 51 (34%)
CNS involvement Yes 10 (10%)
Status of MRD at Tx Positive 45 (49%)
Negative 46 (51%)
Cytogenetics Ph-positive 46 (32%)
Ph-negative 96 (68%)
Normal karyotype 37
Abnormal karyotype 32
t(4;11) 4
t(1;19) 5
t(12;21) 2
Donor age Median (range) 39 (12–74)
F donor/M recipient Yes 63 (30%)
Stem cell source BM 89 (43%)
PB 119 (57%)
CMV D/R Neg to neg 24 (12%)
Pos to neg 20 (10%)
Neg to pos 30 (15%)
Pos to pos 127 (63%)
Donor kinship Parents 49 (37%)
Sibling 51 (38%)
Child 25 (19%)
Others relatives 8 (6%)
Conditioning regimen MAC 137 (66%)
TBI-based (8–12 Gy) 63
Cy TBI 29
Flu TBI 31
Other TBI 3
Chemo-based 74
TBF 38
Bu Cy 1
Bu Flu 3
Flu Mel 2
Table 1 Patients, disease, and transplant characteristics
(Continued)
Treo-based 5
Cy Flu 5
Cy AraC Bu 19
Cy Ida 1
RIC 71 (34%)
TBI based (<6 Gy) 26
Cy TBI 15
Flu TBI 11
Chemo-based 45
TBF 8
Bu Flu 4
Bu ± others 1
Flu Mel 6
Bu Mel 1
Treo-based 11
Cy Flu 11
Cy thiotepa Bu 1
Cy AraC Bu 1
GVHD prophylaxis PT-Cy 118 (57%)
ATG-based 90 (43%)
Abbreviations: Tx transplantation, CR complete remission, ALL acute lymphoblastic
leukemia, MRD minimal residual disease, Ph Philadelphia, CNS central nervous
system, F female, Mmale, PB peripheral blood, BM bone marrow, D donor, R
recipient, neg negative, pos positive, MACmyeloablative conditioning, TBI total body
irradiation, Cy cyclophosphamide, Flu fludarabine, TBF thiotepa, busulphan
fludarabine, Bu busulphan, Mel melphalan, Treo treosulphan, AraC cytarabine, Ida
idarubicine, RIC reduced intensity conditioning, GVHD graft-versus-host-disease,
PT-Cy post transplant cyclophosphamide, ATG anti-thymocyte globulin
In Italics: details of cytogenetics ph negative patients and conditioning details
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OS, LFS, and GRFS were significantly different accord-
ing to disease status: OS was 52% in CR1, 34% in CR2+,
and 4% in advanced disease (p < 0.01); LFS was 47, 33,
and 5 (p < 0.01); and GRFS was 41, 24, and 5 (p < 0.01),
respectively, (Fig. 2a–c).
Figure 3 shows OS and LFS according to the type of
GVHD prophylaxis.
In the multivariate analysis (Table 2), disease status
and the use of PB as stem cell source were found as
negative prognostic factors for OS (CR2+ vs CR1: HR
2.22, 95% CI 1.22–4.03, p < 0.01; advanced vs CR1: HR
3.66, 95% CI 2.06–6.52, p < 0.01; PB vs BM: HR 1.98,
95% CI 1.14–3.42, p < 0.01), for LFS (CR2+ vs CR1: HR
1.91, 95% CI 1.06–3.41, p = 0.02; advanced vs CR1: HR
3.81, 95% CI 2.17–6.67, p < 0.01; PB vs BM: HR 1.81,
95% CI 1.06–3.09, p = 0.02) and for GRFS (advanced vs
CR1: HR 2.71, 95% CI 1.56–4.68, p < 0.01; PB vs BM: HR
1.82, 95% CI 1.10–3.01, p = 0.01).
Discussion
Allo-SCT remains the most effective post-remission
treatment for adults with ALL and is the standard of
care in high-risk patients including those with persistent
or relapsing MRD, steroid and/or chemotherapy-
resistance, and experiencing relapse after initial CR [9].
Several studies reported a 5-year LFS ranging from 40 to
60% in patients in CR1 receiving allogenic transplant-
ation from an HLA-matched sibling or MUD [10–12].
Improvement of results over time has recently been re-
ported [33].
Unfortunately, for a significant proportion of patients,
an HLA identical donor cannot be identified leaving
room for alternative approaches, such as transplanta-
tions from either mismatched unrelated or haploidenti-
cal donors. Thanks to easy access to haploidentical
donors and to the introduction of innovative technologies,
the procedure may be organized fast, avoiding delay
Fig. 1 a aGVHD II–IV. b cGVHD. c relapse. d NRM after haplo-SCT for adults with ALL
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Table 2 Multivariate analysis for outcomes
HR CI p
Relapse
Age (per 10 years) 0.95 0.744–1.217 0.69
Status at Tx
CR1 (reference) 1
CR2+ 1.69 0.72–3.95 0.22
Advanced 8.04 3.76–17.19 <0.01
Ph+ vs Ph− 1.09 0.53–2.24 0.80
KPS≥ 90% 2.02 0.95–4.29 0.06
Female recipient 0.59 0.29–1.20 0.14
Female D ≥male R 0.39 0.18–0.84 0.01
RIC vs MAC 1.32 0.67–2.5 0.41
R CMV positive 1.11 0.45–2.75 0.81
ATG vs PT-Cy 1.15 0.63–2.13 0.63
PB vs BM 1.46 0.68–3.10 0.32
Center (frailty) 0.94
NRM
Age (per 10 years) 0.98 0.72–1.33 0.90
Status at Tx
CR1 (reference) 1
CR2+ 2.15 0.92–5.02 0.07
Advanced 1.50 0.59–3.82 0.39
Ph+ vs Ph− 1.45 0.61–3.42 0.39
KPS≥ 90% 0.23 0.10–0.52 <0.01
Female recipient 1.26 0.52–3.04 0.59
Female D ≥male R 1.47 0.60–3.57 0.39
RIC vs MAC 0.76 0.36–1.60 0.47
R CMV positive 0.57 0.23–1.41 0.22
ATG vs PT-Cy 1.79 0.90–3.55 0.09
PB vs BM 2.56 1.14–5.74 0.02
Center (frailty) 0.94
LFS
Age (per 10 years) 0.98 0.82–1.18 0.89
Status at Tx
CR1 (reference) 1
CR2+ 1.91 1.06–3.41 0.02
Advanced 3.81 2.17–6.67 <0.01
Ph + vs Ph− 1.13 0.66–1.94 0.63
KPS≥ 90% 0.78 0.47–1.29 0.34
Female recipient 0.77 0.45–1.32 0.35
Female D ≥male R 0.72 0.41–1.24 0.24
RIC vs MAC 1.05 0.64–1.72 0.82
R CMV positive 0.73 0.40–1.33 0.31
ATG vs PT-Cy 1.32 0.84–2.06 0.21
PB vs BM 1.81 1.06–3.09 0.02
Table 2 Multivariate analysis for outcomes (Continued)
Center (frailty) 0.9
OS
Age (per 10 years) 1.02 0.84–1.22 0.82
Status at Tx
CR1 (reference) 1
CR2+ 2.22 1.22–4.03 <0.01
Advanced 3.66 2.06–6.52 <0.01
Ph + vs Ph− 1.16 0.67–2.01 0.58
KPS≥ 90% 0.62 0.37–1.02 0.06
Female recipient 0.81 0.47–1.38 0.44
Female D ≥male R 0.76 0.43–1.35 0.36
RIC vs MAC 0.91 0.56–1.48 0.71
R CMV positive 0.81 0.43–1.51 0.51
ATG vs PT-Cy 1.4 0.88–2.20 0.14
PB vs BM 1.98 1.14–3.42 0.01
Center (frailty) 0.92
GRFS
Age (per 10 years) 0.91 0.76–1.08 0.29
Status at Tx
CR1 (reference) 1
CR2+ 1.35 0.78–2.34 0.28
Advanced 2.71 1.56–4.68 <0.01
Ph + vs Ph− 1.20 0.72–2.02 0.47
KPS≥ 90% 0.84 0.50–1.40 0.51
Female recipient 0.70 0.42–1.18 0.18
Female D ≥male R 0.81 0.48–1.38 0.45
RIC vs MAC 1.03 0.65–1.63 0.87
R CMV positive 0.85 0.47–1.53 0.59
ATG vs PT-Cy 1.04 0.67–1.61 0.85
PB vs BM 1.82 1.10–3.01 0.01
Center (frailty) 0.92
aGVHD II-IV
Age (per 10 years) 0.75 0.56–1.00 0.05
Status at Tx
CR1 (reference) 1
CR2+ 1.45 0.696–3.024 0.32
Advanced 0.76 0.29–2.0 0.59
Ph + vs Ph− 1.15 0.52–2.55 0.72
KPS≥ 90% 0.80 0.33–1.93 0.63
Female recipient 1.23 0.53–2.88 0.62
Female D ≥male R 1.84 0.82–4.13 0.13
RIC vs MAC 0.46 0.23–0.93 0.03
R CMV positive 1.28 0.43–3.78 0.65
ATG vs PT-Cy 0.97 0.52–1.81 0.93
PB vs BM 3.00 1.35–6.70 <0.01
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caused by the search of unrelated donor. The attractive-
ness of haplo-SCT should be verified by detailed analysis
of results, as potential advantages may be counterbalanced
by increased risk of immune-related complications. As
well, the impact on the incidence of relapse remains un-
known and may vary according to diagnosis and disease
status. Hence, there is need for studies focusing on
homogenous populations in terms of the diagnosis. In the
current one, the analysis was performed on adults with
ALL, the area that has never been extensively explored.
In the largest report so far, Srour et al. [26] included 109
adults with ALL treated with haplo-SCT with GVHD
prophylaxis uniformly based on PT-Cy. Only 32 patients
were treated in CR1, and estimated 3-year LFS in this sub-
group was 52%. The results of our study including 208 pa-
tients (44% in CR1) correspond well with the previous
ones confirming the feasibility and efficacy of the proced-
ure in this high-risk disease. However, in contrast to the
study by Srour et al., we report results of two types of im-
munosuppressive regimen in the haplo-SCT setting. In
our series, we did not find any difference in the outcome
according to the type of GVHD prophylaxis except for a
trend to increased risk of NRM in ATG group. This effect,
however, did not reach statistical significance. Therefore,
for adults with ALL in the haplo-SCT setting, both types
of GVHD prophylaxis may be successfully used by trans-
plant centers according to their policy.
As expected, disease status was the most important
prognostic factor affecting relapse and survival. While
the outcome of patients treated in CR1 appears compar-
able to results reported for HLA matched SCT in corre-
sponding period [33], results of those with active disease
remain very poor with only 5% OS reported at 3 years.
Pavlu et al. recently reported results of HLA-matched
SCT for patients with primary refractory ALL. The prob-
ability of LFS at 2 years was 28% [34]. However, in the
setting of haplo-SCT results for patients with advanced
disease status remain poor and efforts to achieve disease
remission before transplant are needed. Modern ap-
proaches including bi-specific T cell engaging antibodies
(blinatumomab) [35] or anti-CD22 immunoconjugates
(inotuzumab ozogamycin) [36] have become available
allowing a significant proportion of relapsed/refrac-
tory patients being bridged to SCT. As well, the use
of chimeric antigen receptor (CAR) T cells [37, 38]
is emerging as an effective approach for patients
with lymphoid malignancies resistant to conventional
chemotherapy.
In the study by Pavlu et al., [34] the outcome of pa-
tients with refractory disease was affected by the type of
conditioning and donor/recipient-gender combination
(better results for female donor to male recipient). In
the current study, neither the type nor intensity of the
conditioning had impact on outcome. This is consistent
by previous findings by our group in the setting of un-
manipulated haplo-SCT [39].
In our study, transplants from female donor to male
recipient were associated with significantly reduced risk
of relapse, without major impact on NRM and other
outcomes. This observation suggests that ALL is particu-
larly susceptible to graft-versus-leukemia reaction associ-
ated with mismatches of minor histocompatibility antigen
encoded on Y chromosome.
Two retrospective studies comparing the type of stem
cell source for haplo-SCT with PT-Cy were published
showing no difference in terms of the incidence of
GVHD and survival [40, 41]. Both analyses included RIC
transplants and the populations with various myeloid
and lymphoid malignancies. In contrast to the above-
cited reports, the results of our study indicate a strong
impact of the source of stem cells on outcome of unma-
nipulated haplo-SCT for adults with ALL. The use of PB
was associated with significantly increased risk of acute
GVHD and NRM, which translated into decreased sur-
vival, and leukemia-free survival. It must be stressed,
however, that our population included both MAC and
RIC procedures and different GVHD prophylaxis. The
interaction between these variables and the effect of
stem cell source on outcome should be considered and
requires further exploration. With the rapid increase of
unmanipulated haplo-SCT in the recent era the matter
Table 2 Multivariate analysis for outcomes (Continued)
Center (frailty) 0.93
cGVHD
Age (per 10 years) 0.97 0.69–1.37 0.89
Status at Tx
CR1 (reference) 1
CR2+ 0.58 0.20–1.71 0.33
Advanced 0.62 0.20–1.90 0.40
Ph + vs Ph− 0.86 0.33–2.20 0.75
KPS 90% 0.68 0.26–1.77 0.43
Female recipient 0.93 0.34–2.57 0.90
Female D ≥male R 1.38 0.48–3.94 0.54
RIC vs MAC 0.94 0.38–2.36 0.91
R CMV positive 0.51 0.16–1.56 0.24
ATG vs PT-Cy 0.67 0.25–1.73 0.41
PB vs BM 1.98 0.76–5.14 0.15
Center (frailty) 0.13
Abbreviations: RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free
survival, OS overall survival, GRFS refined graft-versus-host-free, relapse-free survival,
aGVHD acute GVHD, cGVHD chronic GVHD, Tx transplantation, CR complete
remission, Ph Philadelphia, KPS Karnofsky performance status, D donor, R
recipient, MAC myeloablative conditioning, RIC reduced intensity conditioning, ATG
anti-thymocyte globulin, PT-Cy post-transplant cyclophosphamide, PB peripheral
blood, BM bone marrow
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of optimal stem cell source needs to be addressed in lar-
ger homogenous population.
We are aware that in our study, there may be unmeas-
ured factors that have not been considered, and this is a
limitation when conducting retrospective studies. Some
important data on cytogenetics and MRD are lacking,
and also, the choice of the intensity and type of condi-
tioning regimen, GVHD prophylaxis, and stem cell
source are done according to each centers’ protocols
and experience. Furthermore, the population of our
study was homogenous in terms of the diagnosis, but
ALL itself is a heterogeneous disease. In particular,
Fig. 3 a OS. b LFS after haplo according to GVHD prophylaxis
Fig. 2 a OS. b LFS. c GRFS after haplo-SCT for adults with ALL according to disease status
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treatment protocols differ for patients with Ph-positive
and Ph-negative disease. Tyrosine kinase inhibitors are
widely implemented in up-front treatment of Ph-positive
ALL, but their use is also recommended in post-allo-
SCT prophylaxis, which may influence the final outcome
[42]. The retrospective nature of our study did not allow
including this variable in the analysis. As well, data on
minimal residual disease, being the most important
prognostic factor in Ph-negative ALL, were unavailable
[43].
Conclusions
Despite above limitations, our results suggest that unma-
nipulated haplo-SCT is a valuable treatment option for
adults with ALL with the great advantage of being able
to quickly find a donor and avoid the risk of early re-
lapse. Prospective studies are needed to compare the re-
sults of haplo-SCT with other types of donor on an
intention-to-treat basis.
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